Enrollment Begins in Biotronik's BIOVITESSE Trial


October 9, 2017—Biotronik announced the start of enrollment of the BIOVITESSE trial, a coronary stent trial to assess the safety and clinical performance of a new coronary stent in de novo coronary artery lesions. The polymer-free coronary stent combines the features of Biotronik's Pro-Kinetic Energy stent with a new antiproliferative limus drug designed to prevent excessive cell growth.

The BIOVITESSE prospective, multicenter, first-in-man trial will be conducted at five centers in Switzerland through August 2019. Primary endpoints are strut coverage at 1 month and in-stent late lumen loss at 9 months. Strut coverage will be assessed by optical coherence tomography analysis. Late lumen loss will be assessed by quantitative coronary angiography assessment.

The company advised that on September 28, the first implantations in the study were performed by Marco Moccetti, MD, at Cardiocentro Ticino in Lugano, Switzerland, and Lorenz Räber, MD, at University Hospital Bern in Bern, Switzerland.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.